FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 05-660	Serial No. TBA	
INFORMATION DISCI STATEMENT BY APP (Use several sheets if n	PLICANT			
/O % %\	,	Applicant: Phillips		
SEP 0 8 2005 W			Group:	

**U.S. PATENT DOCUMENTS** 

Examiner Initial	Document Number	Date,	Name	Class	Subclass	Filing Date if Appropriate
a	6,669,885	03/02/2004	Phillips			<u></u>
	5,447,918	09/05/1995	McCullough			
	5,840,737	11/24/1998	Phillips			
	6,489,346	01/11/2000	Phillips			
	6,780,882	08/24/2002	Phillips			
	6,183,776	02/06/2001	Depui			

**FOREIGN PATENT DOCUMENTS** 

Document Number					umbe	r		Date	Country	Class	Subclas	Translation	
Document Number						S	Yes	No					
a	0	5	8	4	5	8	8	08/03/1993	EP		<del></del>		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

v	The Carroll Abstract M. Carroll and W. Trudeau, Nas pH, Proceedings of the 10 <sup>th</sup> World Congress Gastroe	The Carroll Abstract M. Carroll and W. Trudeau, N <i>asogastric Administration of Omeprazole for Control of Gastric</i> pH, Proceedings of the 10 <sup>th</sup> World Congress Gastroenterology, October 3, 1994.					
a	M. Horowitz, et al., The Effect of Omeprezole on Gas J. Clin Pharmac. 791-794 (1984).	M. Horowitz, et al., The Effect of Omeprazole on Gastric Emptying in Patients with Duodenal Ulcer Disease, 18 Br. J. Clin Pharmac. 791-794 (1984).					
a	Martindale The Extra Pharmacopeia, Twenty-ninth e Pharmaceutical press 1989.	Martindale The Extra Pharmacopeia, Twenty-ninth edition, Edited by James E.F. Reynolds, London, The Pharmaceutical press 1989.					
EXAMINER	el	DATE CONSIDERED  4(>6(06)					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

PTO/SB/08B U.S. Patent and Trademark Office: U.S. DEPARTMENT OF

SEP 0 9 200	₽ IN	FORMATION FORMATION FOR TATEME
	Sheet	1
A TRADEMA	Sheet	1

لمحضرات يهيبن

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	Complete if Known					
Application Number	10/722184					
Filing Date	November 25, 2003					
First Named Inventor	Phillips					
Art Unit	Unknown					
Examiner Name	Unknown					
Attorney Docket Number	03207556					

		U.	S. PATENT DOC	UMENTS	
Examiner	Cite No. 1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or
tritials*		Number-Kind Code <sup>3</sup> (If known)	MM-DD-YY	Applicant of Cited Document	Relevant Figures Appear
a/		6,780,882	08//24/2004	Phillips	
		···			
		<del></del>			
				/	

	FOREIGN PATENT DOCUMENTS							
Examiner Cite No.	Cite No. 1	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant			
initials*		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>6</sup> (# known)	MM-DD-YY	Applicant of Cited Document	Passages or Relevant Figures Appear	T*		
u		EP 0584588	08/03/1993	Nippon Chemiphar Co., Ltd.				
	<del> </del>	-			1	┢┈		
						L_		

		NON PATENT LITERATURE
Examiner Initials*	Cite No. 1	thouse name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, diy and/or country where published.
u		Request for Ex Parte Reexamination Transmittal Form; Request for Reexamination under 35 USC 302-307 and 37 CFR 1.510 of U.S. Patent No. 6,699,885 filed with the U.S. Patent Office on August 22, 2005, including its Exhibits A, B. B1-9 and C
w		M. Horowitz, et al., The Effect of Omeprazole on Gastric Emptying in Patients with Duodenal Ulcer Disease, 18 Br. J. Clin Pharmac. 791-794 (1984)
K		Martindale The Extra Pharmacopeia, Twenty-ninth Edition, Edited by James E.F. Reynolds, London, The Pharmaceutical Press (1989).

		. — .		
CHDB01 1262652.1 24-Feb-05 16:37	00	Date	. / / .	
		Considered	4126106	
	Λ		,	

"EXAMINER: Initial II reference considered, whether or not citation is in conformance with MPEP 609. Onew line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional). See Nortic Codes of USPTO Patrial Documents to expect www.uspto.gov or MPEP 901.04. "Enter Office that issued the document optional optional optional codes of the related to the related of the patrial document in the related on the document optional patrial document by the appropriate symbots as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English tanguage Translation is distanced.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 33 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any commercia on the amount of time you require to complete this form and/or suggestions for reducing this burders, should be sent to the Chief Information Officer, U.S. Pattern and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SERO FEES OR COMPLETED FORMS TO THIS ADDRESS. SERD TO: Commissioner for Patentia, P.O. Box 1450, Allocandria, VA 22313-1450.
If you need assistance in completing this form, call 1-000-PTO-0199 (1-000-780-0199) and select option 2.

	U.	S. PATENT DOC	UMENTS		
Examiner Initials*	Document Number	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, When Relevant Passages or Relevant Figures Appear	
	Number-Rand Code <sup>2</sup> (if known)			TOOLST TOOLS ALL	
u	5,041,442	08/20/91	Romero et al.		
1	5,703,097	12/30/97	Kim et al.		
	6,280,773	08/28/01	Cho et al.		
a	2001/0053387	12/20/01	Hamied et al.		
	_			<u> </u>	
				T	

	FOREIGN PATENT DOCUMENTS							
Examiner Cite No. 1	Cite No. 1	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant			
		Country Code <sup>1</sup> -Number + Kind Code (If Isnown)	Date MM-DD-YY	Applicant of Cited Document	Passages or Relevant Figures Appear	ľ		
		_						

	NON PATENT LITERATURE					
Examiner Initials*						

Examiner Signature	Cl	Date Considered	4/26/06
	X		

"EXAMINER: Initial if reference considered, whether or not clustion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "Applicant's unique clustion designation number (optional). "See Minds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (MIPO Standard ST.3.)" For Japanese patent documents, the indication of the year of the region of the regions must proceed the section number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. "Applicant is to place a check mark here if English language Translation is stateded.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 15 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and automitting the completed application form to the USPTO. Then will vary depending upon the information of Arthograms on the amount of time you require to complete this form and/or suppositors for reducing this burden, about be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 159, Alexandrid, VA 22313-1450.

DEC 1 6 2004 Substitute for form 1449 500

U.S. Patent and Trademark Office: U.S. DEPARTMEN

## INFORMATIONEDISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

Complete if Known				
10/722,184				
November 25, 20				
Phillips				
1625				
Unknown				
03207556				

Examiner	Cite No. 1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, When Relevant Passages or
initials*		Number-Kind Code <sup>2</sup> (# known)		Applicant of Cited Document	Relevant Figures Appear
a	A1	4620008	10/28/86	Brandstrom, et al.	
i	A2	4628098	12/09/86	Nohara et al.	1
$I^{-}$	A3	4636499	01/13/87	Brandstrom, et al.	
	A4	4689333	08/25/87	Nohara et al.	
	A5	4725691	02/16/88	Brandstrom, et al.	
	A6	5219870,	06/15/93	Kim	
	A7	5232706	08/03/93	Coll	
	A8	5244670	09/14/93	Upson, et al.	
	A9	5288506	02/22/94	Spickett, et al.	
	A10	6068859	05/30/00	Curatolo et al.	
	A11	6262085	07/17/01	Whittle et al.	
	A12	6262086	07/17/01	Whittle et al.	
	A13	6268385	07/31/01	Whittle et al.	
	A14	6489346	12/03/01	Phillips	
	A15	6328993	12/11/01	Linder et al.	
	A16	2003/0144306	07/21/03	Phillips	
	A17	6608091	08/19/03	Whittall et al.	
	A18	6608092	08/19/03	Fujishima et al.	
	A19	6608210	08/19/03	Naka et al.	
	A20	6623759	09/23/03	Heese et al.	
	A21	2003/0181457	09/25/03	Orme et al.	
	A22	2003/0199580	10/23/03	Kishi et al.	
	A23	6645988	11/11/03	Phillips	
	A24	2003/0211147	11/13/03	Cullen et al.	
	A25	6649609	11/18/03	Teuber et al.	1
	A26	2003/0215527	11/20/03	Phillips	1
	A27	2003/0225136	12/04/03	Whittle et al.	
	A28	6664276	12/16/03	Fujishima et al.	1
	A29	6677455	01/13/04	Kronstrom et al.	1
	A30	2004/0010151	01/15/04	Finkelstein et al.	1
	A31	6699885	03/02/04	Phillips	
	A32	2004/0048896	03/11/04	Philips	
10	A33	2004/0058018	03/25/04	Phillips	

Examiner Signature	Cly	Date Considered	41-6606	

"EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional). "See Minds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. "Enter Office that Issued the document, by the two-letter code (MIPO Standard ST.3.)." For Japanese patent documents, the indication of the year of the region of the Emperor must proceed the sected number of the patent document. "York of document by the appropriate symbots as indicated on the document under WIPO Standard ST. 18 if possible. "Applicant is to place a check mark here if English language Translation is stached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to the (and by the USPTO process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and automiting the completed application form to the USPTO. Three will vary depending upon the individual case. Any comments on the amount of time you require to complete this tome and/or supposations for reducing this buttern, about the sent to the Citief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patentia, P.O. Box 159, Alexandrid, VA 22131–1450.

PTO/SB/08B

Substitute for	form 1449/PTO		Complete if Known		
	-001447101		Application Number	10/722,184	
1		DISCLOSURE	Filing Date	November 25, 2003	
ST		BY APPLICANT	First Named Inventor	Phillips	
1	(Use as many sh	eets as necessary)	Art Unit	1625	
ĺ			Examiner Name	Unknown	
Sheet	2	3	Attorney Docket Number	03207556	

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite No. 1	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Unes, Where Relevant		
initiats*		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>8</sup> (If known)	Date MM-DD-YY	Applicant of Cited Document	Passages or Relevant Figures Appear	7*	
11	B1	EP 0040639	12/02/81	7			
Ĭ	B2	EP 0670160	07/14/99				
	В3	EP 1043977	10/22/03				
	B4	EP 1375497	01/02/04				
	B5	JP 51 017268	06/01/76				
	B6	JP 59 095997	06/02/84				
	B7	JP 05 194224	08/03/93				
	B8	WO 8900566	01/26/89				
-	B9	WO 9003184	04/05/90				
	B10	WO 9009175	08/23/90				
	B11	WO 9221331	12/10/92				
	B12	WO 9313138	03/21/95		1		
	B13	WO 95/32958	12/07/95				
	B14	WO 9936060	07/22/99				
	B15	WO 0113919	03/01/01				
	B16	WO 0151050	07/19/01				
	B17	WO 03009846	02/06/03				
	B18	WO 0001372	07/08/03				
	B19	WO 03061584	07/31/03				
de	B20	WO 03063927	08/07/03				

	_	NON PATENT LITERATURE
Examiner Initials*	Cite No. 1	Include name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
d	C1	"Agents for Control of Gastric Acidity and Treatment of Peptic Ulcers", Chapter 37, pp. 907-909, 1768.
	C2	"Buffered and Isotonic Solutions", Physical Pharmacy, Chapter 8, pp. 169-189.
	C3	ADAMS, S. P., et al., "Comments on the Report of 'association' of Omeprazole with DNA by Phillips, et al.", Mutagenesis, Vol. 7, No. 5, pp. 395-396 (September 1992).
	C4	AlHARA, Takeshi et al., "Pharmacological Control of Gastric Acid Secretion for the Treatment of Acid-related Peptic Disease: Past, Present, and Future", Pharmacology & Therapeutics 98, pp. 109-127 (2003).
a	C5	AMERICAN MEDICAL ASSOCIATION, Division of Drugs and Toxicology Department of Drugs, "Drug Evaluations Annual 1992", Vol. 2 (1992).

Examiner Signature	Ob.	Date Considered 4	126106	

"EXAMINER: Initial If reference considered, whether or not cluston is in conformance with MPEP 609. Draw line through cluston if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicant's unique cluston designation number (potions). "See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 601.04. "Enter Office that issued the document," by the wo-lotter code (MPD Standard ST.3." For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sental number of the patent document. "Not of document by the expension as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 33 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suppersions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, Washington, DC 20231. DO NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patentia, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, cast 1-800-PTO-9199 (1-800-788-9199) and acted option 2.

PTO/SB/08B

	U.S. Patent and Tra	idemark Office: U.S. DEPARTMENT OF COMMERCE
Substitute for form 1449/PTO	Comp	olete if Known
	Application Number	10/722,184
INFORMATION DISCLOSURE	Filing Date	November 25, 2002

1 1 2 v

November 25, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor **Phillips** (Use as many sheets as necessary) Art Unit 1625 Examiner Name Unknown Attorney Docket Number 03207556 3 3 Sheet

a		C6	HUBER, R., "Pharmacokinetics of Pantoprazole in Man", <u>International Journal of Clinical</u> Pharmacology and Therapeutics, Vol. 34, No. 5, pp. 185-194 (1996)
		C7	LEY, B. et al., "Bioavailability of a Crushed Pantoprazole Tablet after Buffering with Sodium Hydrogencarbonate or Magaldrate Relative to the Intact Enteric Coated Pantoprazole Tablet", Methods and Findings in Experimental and Clinical Pharmacolgy, Vol. 23, pp. 41-45 (2001).
		C8	"Supplemental Information Disclosure Statement" as filed with U.S. Patent and Trademark Office on December 21, 2001 for U.S. Application No. 09/481,207 (U.S. Patent 6,489,346.
		C9	MARTIN, L., et al., "Stress Ulcers and Organ Failure in Intubated Patients in Surgical Intensive Care Units", <u>Ann. Surg.</u> , Vol. 215, No. 4, (April 1992).
		C10	PHILLIPS, J., et al., "A Randomized, Pharmacokinetic and Pharmacodynamic, Crossover Study of Duodenal of Jejunal Administration Compared to Nasogastric Administration of Omeprazole Suspension in Patients at Risk for Stress Ulcers", The American Journal of Gastroenterology, Vol. 96, No. 2 (2001)
N		C11	TABATA, T. et al., "Stabilization of a New Antiulcer Drug (Lansorprazole) in the Solid Dosage Forms", <u>Drug Development and Industrial Pharmacy</u> , Vol. 18, pp. 1437-1447 (1992).
ļ			
	_		,
	$\dashv$		
	$\dashv$		

Examiner	21	Date	-6~	(5/7		
Signature	$(V_{\gamma})$	Considered	71	1 9c	00	
			$\rightarrow$	<del>- t</del>		

"EXAMINER: initial if reference considered, whether or not cluston is in conformance with MPEP 809. Draw line through cluston if not in conformance and not considered. Include copy of this form with next communication to applicant. "Applicant's unique cluston designation number (options). "See Nicks Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patent document, the indication of the year of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including cathering, preparing, and submitting the completed application form to the USPTO. There will vary depending upon the windwidual case. Any comments on the amount of time you require to complete the pum and/or suppositions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patentia, P.O. Box 159, Alexandria, V.A. 22313-1450.